Xiaolin Li

3 weeks ago | dx.doi.org | Xiaolin Li |Yingyu Zhao |Ming Liu |Mingyi Zhang

Jan 23, 2025 | nature.com | Ai-Min Li |Peter Y. Zavalij |Xiaolin Li |Chunsheng Wang |Fred Omenya

Room-temperature non-aqueous sodium metal batteries are viable candidates for cost-effective and safe electrochemical energy storage. However, they show low specific energy and poor cycle life as the use of conventional organic-based non-aqueous electrolyte solutions enables the formation of interphases that cannot prevent degradations at the positive and negative electrodes. Here, to promote the formation of inorganic NaF-rich interphases on both negative and positive electrodes, we propose the salt-in-presalt (SIPS) electrolyte formulation strategy. In SIPS, sodium bis(fluorosulfonyl)imide (NaFSI) salt is dissolved in the liquid precursor of the sodium bis(trifluoromethylsulfonyl)imide (NaTFSI) salt, that is, N,N-dimethyltrifluoromethane-sulfonamide, called PreTFSI. The prepared 0.5 M NaFSI in PreTFSI (SIPS5) electrolyte solution shows an electrochemical stability up to 6.7 V versus Na|Na+ and enables a Na stripping/plating average Coulombic efficiency of 99.7% at 2.0 mA cm−2 and 4.0 mAh cm−2 in Na||Al cell configuration. By testing SIPS5 in Na metal and ‘anode-less’ coin and pouch cell configurations using NaNi0.6Mn0.2Co0.2O2 or sulfurized polyacrylonitrile as positive electrode active materials, we demonstrate the ability of the SIPS strategy to deliver improved specific discharge capacity and capacity retentions at high cell potentials and moderate applied specific currents for cell cycle life up to 1,000 cycles. The specific energy and cycle life of rechargeable non-aqueous Na-based batteries are influenced by the type of electrolyte used. Here the authors propose a sulfonyl imide-rich electrolyte solution to improve the energy content and life span of various Na-based batteries.

Jul 21, 2024 | mdpi.com | Xiaolin Li |Feng Hua Ding |Bo Xiong |Ge Chen

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jun 25, 2024 | pericles.pericles-prod.literatumonline.com | Kaiming Li |Xiaolin Li |Jie Wu |Haisi Wu

Conflict of Interest The authors declare that they have no conflict of interest. Supporting Information Filename Description adfm202404956-sup-0001-SuppMat.docx11 MB Supporting Information References 1a) , Science 2013, 342, 1432; b) , Annu. Rev. Immunol. 2012, 30, 1. 2, , , Nat Rev Urol 2023, 20, 544. 3a) , , , , Adv Drug Deliv Rev 2021, 177, 113927; b) , , Nat. Commun. 2019, 10, 5408. 4a) , , , , , , Nat. Rev. Immunol.